113 studies found for:    30607
Show Display Options
Rank Status Study
1 Active, not recruiting Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy
Conditions: Stage IIIB Non-small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
Interventions: Drug: sunitinib malate;   Other: placebo;   Other: quality-of-life assessment;   Other: laboratory biomarker analysis
2 Completed Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer
Conditions: Recurrent Breast Cancer;   Stage IIIB Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: tamoxifen citrate;   Drug: letrozole;   Biological: bevacizumab;   Other: laboratory biomarker analysis;   Other: questionnaire administration
3 Active, not recruiting The BEACON Study (Breast Cancer Outcomes With NKTR-102)
Conditions: Locally Recurrent Breast Cancer;   Metastatic Breast Cancer
Interventions: Drug: NKTR-102;   Drug: Treatment of Physician's Choice (TPC)
4 Active, not recruiting Thyroid Dysfunction in Women With Newly Diagnosed Breast Cancer Compared to Healthy Volunteers
Conditions: Breast Cancer;   Fatigue;   Hypothyroidism
Interventions: Other: physiologic testing;   Procedure: fatigue assessment and management;   Procedure: management of therapy complications
5 Recruiting Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study
Condition: Myelodysplastic Syndromes
Interventions: Drug: Deferasirox;   Drug: Deferasirox placebo
6 Recruiting Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO
Condition: Non Small Cell Lung Cancer (NSCLC)
Interventions: Drug: Dacomitinib Plus Blinded Doxycycline or Placebo;   Drug: Dacomitinib Plus Probiotic Plus Topical Alclometasone cream;   Drug: Dacomitinib
7 Terminated Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta)
Condition: Follicular Lymphoma
Interventions: Drug: Zevalin;   Drug: Rituximab
8 Not yet recruiting A Study of LY2835219 Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer
Condition: Breast Neoplasms
Interventions: Drug: LY2835219;   Drug: Fulvestrant;   Drug: Placebo
9 Active, not recruiting Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery
Conditions: Stage IB Non-small Cell Lung Cancer;   Stage IIA Non-small Cell Lung Cancer;   Stage IIB Non-small Cell Lung Cancer;   Stage IIIA Non-small Cell Lung Cancer
Interventions: Drug: gemcitabine hydrochloride;   Drug: vinorelbine tartrate;   Drug: cisplatin;   Drug: docetaxel;   Drug: pemetrexed disodium;   Biological: bevacizumab;   Other: questionnaire administration;   Other: laboratory biomarker analysis
10 Unknown  Treatment of HER2-Positive Metastatic Breast Cancer With Herceptin and Bevacizumab (Antibodies Against HER2 and VEGF)
Condition: Breast Cancer
Intervention: Drug: Bevacizumab (drug), Herceptin (drug)
11 Terminated
Has Results
Alternative Schedule of Velcade/Dexamethasone Plus Doxil for Patients With Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: bortezomib;   Drug: dexamethasone;   Drug: doxorubicin HCl liposome
12 Completed Phase 2 Study Comparing Two Dose Schedules of Telintra™ in Myelodysplastic Syndrome (MDS)
Condition: Myelodysplastic Syndrome (MDS)
Intervention: Drug: Ezatiostat Hydrochloride
13 Active, not recruiting A Study Comparing Bevacizumab Therapy With or Without Erlotinib for First-Line Treatment of Non-Small Cell Lung Cancer (ATLAS)
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: bevacizumab;   Drug: placebo;   Drug: erlotinib HCl
14 Active, not recruiting Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Panobinostat;   Drug: Bortezomib
15 Completed Pemetrexed Disodium and Gemcitabine in Treating Patients With Advanced Cancer of the Urothelium
Conditions: Bladder Cancer;   Transitional Cell Cancer of the Renal Pelvis and Ureter;   Urethral Cancer
Interventions: Drug: gemcitabine hydrochloride;   Drug: pemetrexed disodium
16 Completed Rheumatological Evaluation of Anastrozole and Letrozole as Adjuvant Treatment in Post-menopausal Women With Breast Cancer
Condition: Breast Cancer
Intervention: Drug: letrozole
17 Active, not recruiting Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer
Conditions: Estrogen Receptor-negative Breast Cancer;   Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   Male Breast Cancer;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: doxorubicin hydrochloride;   Drug: cyclophosphamide;   Drug: paclitaxel;   Biological: bevacizumab;   Other: placebo;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment
18 Recruiting S0819: Carboplatin/Paclitaxel With or Without Bevacizumab and/or Cetuximab in Stage IV or Recurrent Non-Small Cell Lung Cancer
Condition: Lung Cancer
Interventions: Biological: bevacizumab;   Biological: cetuximab;   Drug: carboplatin;   Drug: paclitaxel
19 Recruiting LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: LDK378;   Drug: pemetrexed;   Drug: docetaxel
20 Active, not recruiting Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST)
Condition: Gastrointestinal Stromal Tumor (GIST)
Intervention: Drug: imatinib mesylate

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years